Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced the presentation of clinical study results for its drug olverembatinib (HQP1351) at the 2024 European Society of Medical Oncology (ESMO) Congress. The study focused on patients with succinate dehydrogenase-deficient gastrointestinal stromal tumor (GIST), a rare and aggressive form of cancer.
The data demonstrated sustained clinical benefits for patients with SDH-deficient GIST. As of March 12, 2024, partial responses (PRs) were observed in six out of 26 enrolled patients, with an objective response rate (ORR) of 23.1% and a median progression-free survival (PFS) of 22 months. Mechanism of action (MOA) studies indicated that olverembatinib modulates multiple signaling pathways associated with angiogenesis, apoptosis, proliferation, and survival, contributing to its antitumor activity.
Olverembatinib, a novel orally-administered tyrosine kinase inhibitor (TKI) developed by Ascentage Pharma, is the first approved third-generation BCR-ABL inhibitor in China. It has been approved for two indications: adult patients with TKI-resistant chronic-phase chronic myeloid leukemia (CML-CP) or accelerated-phase CML (CML-AP) with the T315I mutation, and adult patients with CML-CP resistant to and/or intolerant of first- and second-generation TKIs. In China, olverembatinib is jointly commercialized by Ascentage Pharma and Innovent Biologics. – Flcube.com
